Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease

Area of Science:

• Hematology
• Oncology

Background:

• Hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), and mast cell disease (MCD) are myeloproliferative neoplasms.
• Accurate diagnosis is crucial for appropriate management and distinguishing between these conditions.

Purpose of the Study:

• To outline diagnostic criteria and current therapeutic strategies for HES, CEL, and MCD.
• To highlight the importance of molecular and cytogenetic studies in diagnosing these disorders.

Main Methods:

• Bone marrow examination with cytogenetic and molecular studies for diagnosis.
• Tryptase immunostaining and immunophenotyping for MCD diagnosis.
• Mutation screening for KITD816V in MCD and specific gene mutations in CEL.

Main Results:

• HES and indolent MCD may not require immediate therapy if asymptomatic with no organ damage.
• Effective treatments include corticosteroids, interferon-alpha (IFN-alpha), hydroxyurea for HES, imatinib for specific CEL types, and IFN-alpha and cladribine for MCD.
• New drugs are under investigation for HES, CEL, and MCD.

Conclusions:

• Diagnostic approaches for HES, CEL, and MCD involve specialized bone marrow and molecular analyses.
• Current therapies are available, with ongoing research for novel treatments to improve outcomes for patients with these myeloproliferative neoplasms.